Viel, T. et al., Mol. Imaging, 7, 239-47 (2008).
8. Falguières, T. et al., Mol. Cancer Ther., 7, 2498-
508 (2008).
9. Engedal, N. et al., Microb. Biotechnol., 4, 32–46
(2011).
SG,DR,OKF
. Biophys.
Acta, 455, 796-508 (1976).
3. Le Maire, M. et al., Eur. J. Biochem., 129, 525-532
(1983).
4. Neugebauer, J.M. et al., Methods in Enzymology,
182, 239-282 (1990).
5. Supplier data
. No. 47-239) were analyzed with the Human OXPHOS Magnetic Bead Panel
according to the assay protocol. The Median Fluorescence Intensity (MFI) was measured with a
Luminex® system.
Figure 4. Multiplexed
active 14-525 3
PKCη, active 14-497 3
PKCΘ, active 14-444 3
PKCι, active 14-505 3
PKCμ, active 14-508 3
PKD2, active 14-506 3
PKG1α, active 14-688 3
PKG1β, active 14-650 3
PKR agarose, active 14-423
Plk1
PSR) P1495 23210 JMJD6 P NP_001074930.1 y y n/d
42 ASPP1 A4355 23368 PPP1R13B M NP_056131.2 y y n/d
508 Nicastrin N1660 23385 NCSTN P NP_056146.1 y y y
221 DEDAF D3316 23429 RYBP P NP_036366.3 y y y
549
PSR) P1495 23210 JMJD6 P NP_001074930.1 y y n/d
42 ASPP1 A4355 23368 PPP1R13B M NP_056131.2 y y n/d
508 Nicastrin N1660 23385 NCSTN P NP_056146.1 y y y
221 DEDAF D3316 23429 RYBP P NP_036366.3 y y y
549
PSR) P1495 23210 JMJD6 P NP_001074930.1 y y n/d
42 ASPP1 A4355 23368 PPP1R13B M NP_056131.2 y y n/d
508 Nicastrin N1660 23385 NCSTN P NP_056146.1 y y y
221 DEDAF D3316 23429 RYBP P NP_036366.3 y y y
549
505 NF-κB N8523 M y y n/d
506 NAK (NFκB-Activating Kinase) N2661 M y n/d y
507 NG2 N8912 M n/d n/d y
508 Nicastrin N1660 P y n/d n/d
509 Nitric Oxide Synthase, Brain (b-NOS) y ( ) N2280 M y n/d y
510
362887 Tbk1_predicted,TBK1 NP_037386.1, M y n/d y
507 NG2 N8912 81651 Cspg4 NP_112284.1 M n/d n/d y
508 Nicastrin N1660 23385 NCSTN NP_056146.1 P y n/d n/d
509 Nitric Oxide Synthase, Brain (b-NOS) N2280
362887 Tbk1_predicted,TBK1 NP_037386.1, M y n/d y
507 NG2 N8912 81651 Cspg4 NP_112284.1 M n/d n/d y
508 Nicastrin N1660 23385 NCSTN NP_056146.1 P y n/d n/d
509 Nitric Oxide Synthase, Brain (b-NOS) N2280